medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2021, Number 2

<< Back Next >>

Rev Latin Infect Pediatr 2021; 34 (2)

Use of nitazoxanide in viral infections

Romero-Cabello R, Romero-Feregrino R, Romero-Feregrino R, Amancio CO

Language: Spanish
References: 26
Page: 94-99
PDF size: 172.94 Kb.


ABSTRACT

Nitazoxanide as of 2019 was shown to inhibit replication of Ebola virus and vesicular stomatitis, amplify host antiviral response, suppresses the production of proinflammatory cytokines in mononuclear cells, inhibits interleukin 6 (IL-6) synthesis, stimulates the innate immune system and attenuates the immune and inflammatory response. It has action against MERS-CoV and other coronaviruses, has antiviral activity against respiratory viruses influenza A and B and parainfluenza. Tizoxanide reaches effective inhibitory concentrations to produce its antiviral effect in different organs and in vitro activity against SARS-CoV-2, by amplification of antiviral interferon response, increases RIG-1 (cytoplasmic RNA sensor), GADD34 (protein induces DNA damage and growth arrest), PKR (protein kinase R) and effectors MAVS, interferons and multiple ISGs (interferon stimulator genes). In addition to inhibiting the production of proinflammatory cytokines. A decrease in SAR-CoV-2 viral load and improvement of clinical manifestations in cases of COVID-19 was observed with nitazoxanide.


REFERENCES

  1. Pizzorno A, Padey B, Terrier O, Rosa-Calatrava M. Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy. Front Immunol. 2019; 10: 531. doi: 10.3389/fimmu.2019.00531.

  2. Rossignol JF. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014; 110: 94-103.

  3. Jasenosky LD, Cadena C, Mire CE et al. The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits Ebola virus. iScience. 2019; 19: 1279-1290.

  4. Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 2016; 9 (3): 227-230.

  5. Trabattoni D, Gnudi F, Ibba SV et al. Thiazolides elicit anti-viral innate immunity and reduce HIV replication. Sci Rep. 2016; 6: 27148. doi: 10.1038/srep27148.

  6. University of Alberta. Departments of Computing Science & Biological Sciences; The Metabolomics Innovation Centre, DrugBank. Nitazoxanide. [Consultado 5 de febrero de 2020] Disponible en: www.drugbank.ca/drugs/DB00507

  7. PR Vademecum. Nitazoxanida. [Consultado 21 de marzo de 2020] Disponible en: https://mx.prvademecum.com/principio-activo/nitazoxanida-2760//

  8. Welzel DM, Philips MA. Chemotherapy of protozoal infection amebiasis, giardiasis, trichomoniasis, trypanosomiasis, leishmaniasis and other protozoal infection. In: Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman &Gilman. The pharmaceutical basis of therapeutics. 13 ed. New York, USA: McGraw Hill Education; 2018. pp. 987-99.

  9. Nitazoxanida tablets. Clinical pharmaceutical and biopharmaceutical reviews, No 21-497, 2004. [Consultado 28 de abril de 2020] Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-497_Alinia_BioPharmr.pdf

  10. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. A reference guide to fetal and neonatal risk. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. pp. 1308-1309.

  11. Hadad GM, Abdel-Salam RA, Emara S. Validated and optimized high performance liquid chromatographic determination of tizoxanide, the main active metabolite of nitazoxanide in human urine, plasma and breast milk. J Chromatogr Sci. 2012; 50: 509-515.

  12. Haffizulla J, Hartman A, Hoppers M et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2014; 14 (7): 609-618.

  13. Piacentini S, La Frazia S, Riccio A et al. Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57. Sci Rep. 2018; 8 (1): 10425. doi: 10.1038/s41598-018-28172-9.

  14. Tan E, Cawcutt K, Zomok C et al. Activity of nitazoxanide against viral gastroenteritis: a systematic review. Int J Travel Med Glob Health. 2017; 5 (4): 107-112.

  15. Rossignol JF, Bréchot C. A pilot clinical trial of nitazoxanide in the treatment of chronic hepatitis B. Hepatol Commun. 2019; 3 (6): 744-747.

  16. Keeffe E, Rossignol JF. Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides. World J Gastroenterol. 2009; 15 (15): 1805-1808.

  17. Arshad U, Pertinez H, Box H et al. Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics. Clin Pharmacol Ther. 2020; 108 (4): 775-790. doi: 10.1002/cpt.1909.

  18. Srivatsan Padmanabhan M, Tech KPM. Nitazoxanide–a potential ally in the treatment of COVID-19. 2020. doi: 10.13140/RG.2.2.22854.83527.

  19. Mahmoud DB, Shitu Z, Mostafa A. Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19? J Genet Eng Biotechnol. 2020; 18 (1): 35.

  20. Padmanabhan S. Potential dual therapeutic approach against SARS-CoV-2/COVID-19 with nitazoxanide and hydroxychloroquine. ResearchGate. 2020. doi: 10.13140/RG.2.2.28124.74882.

  21. Khatri M, Mago P. Nitazoxanide/Camostat combination for COVID-19: an unexplored potential therapy. Chem Biol Lett. 2020; 7 (3): 192-196.

  22. Pepperrell T, Pilkington V, Owen A, Wang J, Hill AM. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. J Virus Erad. 2020; 6 (2): 52-60.

  23. Dos Santos WG. Natural history of COVID-19 and current knowledge on treatment therapeutic options. Biomed Pharmacother. 2020; 129: 110493.

  24. Rocco PRM, Silva PL, Cruz FF et al. Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial. Eur Respir J. 2021. doi: 10.1183/13993003.03725-2020.

  25. Meneses Calderón J, Figueroa Flores MDR, Paniagua Coria L, Briones Garduño JC, Meneses Figueroa J, Vargas Contretas MJ et al. Nitazoxanide against COVID-19 in three explorative scenarios. J Infect Dev Ctries. 2020; 14 (9): 982-986.

  26. Silva M, Espejo A, Pereyra M, Lynch M, Thompson M, Taconelli H et al. Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel-group, pilot study. medRxiv. 2021. Available in: https://doi.org/10.1101/2021.03.03.21252509




2020     |     www.medigraphic.com